Evidence map›Paper›PMID 29679893›Full record

ArticleRedox biology2018

Identification of homocysteine-suppressive mitochondrial ETC complex genes and tissue expression profile - Novel hypothesis establishment.

Ramon Cueto, Lixiao Zhang, Hui Min Shan, Xiao Huang, Xinyuan Li, Ya-Feng Li, Jahaira Lopez, William Y Yang, Muriel Lavallee, Catherine Yu and 3 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Folic acid-induced animal model of kidney disease.Animal models and experimental medicine · 2021
    Review
  14. Article
  15. Article
  16. Homocysteine and Mitochondria in Cardiovascular and Cerebrovascular Systems.International journal of molecular sciences · 2020
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Ramon CuetoCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Lixiao ZhangCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Hui Min ShanCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Xiao HuangCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Xinyuan LiCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Ya-Feng LiCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Jahaira LopezCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
William Y YangCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Muriel LavalleeCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA.
Catherine YuCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA; The Geisinger Commonwealth School of Medicine, Scranton, PA, USA.
Yong JiKey Laboratory of Cardiovascular Disease and Molecular Intervention, Nanjing Medical University, Nanjing 210029, China. Electronic address: yongji@njmu.edu.cn.
Xiaofeng YangCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA; Department of Pharmacology, Temple University - Lewis Katz School of Medicine, Philadelphia, PA, USA; Thrombosis Research Center, Temple University - Lewis Katz School of Medicine, Philadelphia, PA, USA; Cardiovascular Research Center, Temple University - Lewis Katz School of Medicine, Philadelphia, PA, USA.
Hong WangCenter for Metabolic Disease Research, Temple University - Lewis Katz School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA; Department of Pharmacology, Temple University - Lewis Katz School of Medicine, Philadelphia, PA, USA; Thrombosis Research Center, Temple University - Lewis Katz School of Medicine, Philadelphia, PA, USA; Cardiovascular Research Center, Temple University - Lewis Katz School of Medicine, Philadelphia, PA, USA. Electronic address: hongw@temple.edu.
Temple University · USGeisinger Commonwealth School of Medicine · USNanjing Medical University · CN

Funding

Atherogenic mechanisms with homocysteineR01HL077288 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2004 to 2014
$3.8M
CD40 monocyte in chronic kidney diseaseR01DK113775 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2017 to 2021
$3.3M
Inhibition of Endothelial Growth by HomocysteineR01HL067033 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2002 to 2011
$3.0M
Hyperhomocysteinemia and HDL MetabolismR01HL117654 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2013 to 2017
$3.0M
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosisR01HL131460 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CHOI, ERIC T., WANG, HONG · 2016 to 2019
$2.8M
The roles of miR-155 in regulating atherosclerosis and metabolically healthy obesityR01HL138749 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.6M
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcyR01HL110764 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2011 to 2015
$2.5M
Atherogenic roles of complement systemR01HL130233 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI QIN, XUEBIN, WANG, HONG · 2016 to 2019
$2.5M
IL-35 suppression of endothelial cell activation and atherosclerosisR01HL132399 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.3M
Roles of Interleukin-17 in Endothelial CellsR01HL108910 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2011 to 2015
$1.9M
Role of HHcy in diabetic vascular diseaseR01HL082774 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2006 to 2010
$1.8M
HHcy-induced Bax upregulation, Treg apoptosis and vascular diseaseR01HL116917 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2013 to 2016
$1.6M
NHLBI NIH HHS F32 HL009445NHLBI NIH HHS R01 HL067033NHLBI NIH HHS R01 HL077288NHLBI NIH HHS R01 HL082774NHLBI NIH HHS R01 HL108910NHLBI NIH HHS R01 HL110764NHLBI NIH HHS R01 HL116917NHLBI NIH HHS R01 HL117654NHLBI NIH HHS R01 HL130233NHLBI NIH HHS R01 HL131460NHLBI NIH HHS R01 HL132399NHLBI NIH HHS R01 HL138749NIDDK NIH HHS R01 DK113775
6 · The paper itself

Abstract

Hyperhomocysteinemia (HHcy) is an independent risk factor for cardiovascular disease (CVD) which has been implicated in matochondrial (Mt) function impairment. In this study, we characterized Hcy metabolism in mouse tissues by using LC-ESI-MS/MS analysis, established tissue expression profiles for 84 nuclear-encoded Mt electron transport chain complex (nMt-ETC-Com) genes in 20 human and 19 mouse tissues by database mining, and modeled the effect of HHcy on Mt-ETC function. Hcy levels were high in mouse kidney/lung/spleen/liver (24-14 nmol/g tissue) but low in brain/heart (~5 nmol/g). S-adenosylhomocysteine (SAH) levels were high in the liver/kidney (59-33 nmol/g), moderate in lung/heart/brain (7-4 nmol/g) and low in spleen (1 nmol/g). S-adenosylmethionine (SAM) was comparable in all tissues (42-18 nmol/g). SAM/SAH ratio was as high as 25.6 in the spleen but much lower in the heart/lung/brain/kidney/liver (7-0.6). The nMt-ETC-Com genes were highly expressed in muscle/pituitary gland/heart/BM in humans and in lymph node/heart/pancreas/brain in mice. We identified 15 Hcy-suppressive nMt-ETC-Com genes whose mRNA levels were negatively correlated with tissue Hcy levels, including 11 complex-I, one complex-IV and two complex-V genes. Among the 11 Hcy-suppressive complex-I genes, 4 are complex-I core subunits. Based on the pattern of tissue expression of these genes, we classified tissues into three tiers (high/mid/low-Hcy responsive), and defined heart/eye/pancreas/brain/kidney/liver/testis/embryonic tissues as tier 1 (high-Hcy responsive) tissues in both human and mice. Furthermore, through extensive literature mining, we found that most of the Hcy-suppressive nMt-ETC-Com genes were suppressed in HHcy conditions and related with Mt complex assembly/activity impairment in human disease and experimental models. We hypothesize that HHcy inhibits Mt complex I gene expression leading to Mt dysfunction.

Indexed as

AnimalsCardiovascular DiseasesElectron Transport Chain Complex ProteinsGene Expression RegulationHumansHyperhomocysteinemiaKidneyLungMiceMitochondriaOrgan SpecificityRisk FactorsS-AdenosylmethionineSpleenElectron Transport Chain Complex ProteinsS-AdenosylmethionineDatabase miningHomocysteine metabolismTissue expression profile

Identifiers

PMID29679893
PMCPMC6006524
OpenAlexW2796465165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.